Evotec SE (EVO)
NASDAQ: EVO · IEX Real-Time Price · USD
4.950
+0.090 (1.85%)
At close: Jul 2, 2024, 4:00 PM
4.980
+0.030 (0.61%)
After-hours: Jul 2, 2024, 6:34 PM EDT
Evotec SE Revenue
Revenue in the quarter ending September 30, 2023 was $208.81M with 15.19% year-over-year growth. In the year 2022, Evotec SE had annual revenue of $799.41M with 13.83% growth.
Revenue (ttm)
$799.41M
Revenue Growth
+13.83%
P/S Ratio
n/a
Revenue / Employee
$161,432
Employees
4,952
Market Cap
1.76B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 799.41M | 97.10M | 13.83% |
Dec 31, 2021 | 702.31M | 91.43M | 14.97% |
Dec 31, 2020 | 610.88M | 109.27M | 21.78% |
Dec 31, 2019 | 501.61M | 440.41M | 719.61% |
Dec 31, 2009 | 61.20M | 6.00M | 10.86% |
Dec 31, 2008 | 55.21M | 7.14M | 14.85% |
Dec 31, 2007 | 48.07M | -5.32M | -9.96% |
Dec 31, 2006 | 53.39M | 3.96M | 8.00% |
Dec 31, 2005 | 49.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teladoc Health | 2.62B |
National HealthCare | 1.17B |
Harmony Biosciences Holdings | 617.51M |
Veracyte | 375.47M |
Zai Lab | 291.07M |
Immunocore Holdings | 264.25M |
Recursion Pharmaceuticals | 46.24M |
EVO News
- 8 days ago - Just - Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program - Accesswire
- 21 days ago - Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb - Accesswire
- 22 days ago - Evotec SE: Results of the Annual General Meeting 2024 - Accesswire
- 6 weeks ago - Evotec SE to Announce Results for First Quarter 2024 on 22 May 2024 - Accesswire
- 2 months ago - Bayer and Evotec Collaborate to Advance Precision Cardiology - Accesswire
- 2 months ago - Evotec shares lose a third of their value on cloudy outlook - Market Watch
- 2 months ago - Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth - Accesswire
- 2 months ago - Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer - Accesswire